Lymphoma / Leukemia Clinical Trials
For more information about a clinical trial,
clinical trial eligibility, or informed consent,
contact our research nurses by phone or email:
Please Note: The eligibility criteria noted below are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any treatment to be undertaken must ultimately be determined on an individual basis by the patient and those involved in the patient's treatment. |
Hematologic Clinical Trials
| There are no clinical trials of this type currently accepting new members. |
|---|
Hodgkin Clinical Trials
| Study Title | ||||
|---|---|---|---|---|
| Body Location | Study # | Primary Investigator | More Info | |
Functional Performance of Older Adults with Cancer | ||||
| Breast-Female, Colon, Esophagus, Hodgkins Lymphoma, Kidney, Leukemia, Other, Leukemia, not otherwise specified, Liver, Lung, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia, Non-Hodgkins Lymphoma, Prostate, Rectum, Small Intestine, Stomach, Urinary Bladder | D0836 | Lyons | More Info | |
Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation | ||||
| Hodgkins Lymphoma, Leukemia, Other, Leukemia, not otherwise specified, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia, Non-Hodgkins Lymphoma, Other Hematopoietic | D0748 | Zuckerman | More Info | |
A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma | ||||
| Non-Hodgkins Lymphoma | C50403 | Bengtson | More Info | |
A Phase II Trial of Bortezomib (NSC #681239) + Lenalidomide (Revlimid, CC-5013) (NSC #703813) for Relapsed/Refractory Mantle Cell Lymphoma | ||||
| Non-Hodgkins Lymphoma | C50501 | Bengtson | More Info | |
A Phase III Multicenter, Open-Label Study Of Rituximab Faster Infusion Time in Patients with Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma | ||||
| Non-Hodgkins Lymphoma | F0840 | Bengtson | More Info | |
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma | ||||
| Non-Hodgkins Lymphoma | F0843 | Bengtson | More Info | |
Leukemia Clinical Trials
| Study Title | ||||
|---|---|---|---|---|
| Body Location | Study # | Primary Investigator | More Info | |
Functional Performance of Older Adults with Cancer | ||||
| Breast-Female, Colon, Esophagus, Hodgkins Lymphoma, Kidney, Leukemia, Other, Leukemia, not otherwise specified, Liver, Lung, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia, Non-Hodgkins Lymphoma, Prostate, Rectum, Small Intestine, Stomach, Urinary Bladder | D0836 | Lyons | More Info | |
Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation | ||||
| Hodgkins Lymphoma, Leukemia, Other, Leukemia, not otherwise specified, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia, Non-Hodgkins Lymphoma, Other Hematopoietic | D0748 | Zuckerman | More Info | |
Multidrug Resistance Studies in Acute Leukemia | ||||
| Leukemia, Other, Leukemia, not otherwise specified | C9760 | Lowrey | More Info | |
Cytogenetic Studies in Acute Leukemia | ||||
| Leukemia, not otherwise specified | C8461 | Lowrey | More Info | |
The CALGB Leukemia Tissue Bank | ||||
| Leukemia, not otherwise specified | C9665 | Lowrey | More Info | |
A Phase II Trial of Sequential Chemotherapy, Imatinib Mesylate (Gleevec, STI571) (NSC#716051, IND#61135) and Transplantation for Adults with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by the CALGB and SWOG | ||||
| Lymphoid Leukemia | C10001 | Hill | More Info | |
Molecular Markers of Chronic Lymphocytic Leukemia | ||||
| Lymphoid Leukemia | C20203 | Gautier | More Info | |
Protocol to Obtain Blood Samples for Chronic Lymphocytic Leukemia Research | ||||
| Lymphoid Leukemia | D0905 | Lowrey | More Info | |
Phase II Study of Maintenance Therapy with Decitabine (NSC #127716, IND #50733) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients with AML < 60 Years | ||||
| Myeloid and Monocytic Leukemia | C10503 | Lowrey | More Info | |
Non-Hodgkin Clinical Trials
| Study Title | ||||
|---|---|---|---|---|
| Body Location | Study # | Primary Investigator | More Info | |
Functional Performance of Older Adults with Cancer | ||||
| Breast-Female, Colon, Esophagus, Hodgkins Lymphoma, Kidney, Leukemia, Other, Leukemia, not otherwise specified, Liver, Lung, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia, Non-Hodgkins Lymphoma, Prostate, Rectum, Small Intestine, Stomach, Urinary Bladder | D0836 | Lyons | More Info | |
Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation | ||||
| Hodgkins Lymphoma, Leukemia, Other, Leukemia, not otherwise specified, Lymphoid Leukemia, Multiple Myeloma, Myeloid and Monocytic Leukemia, Non-Hodgkins Lymphoma, Other Hematopoietic | D0748 | Zuckerman | More Info | |
A Randomized Phase II Trial of Maintenance vs Consolidation Bortezomib Therapy Following Aggressive Chemo-Immunotherapy and Autologous Stem Cell Transplant for Previously Untreated Mantle Cell Lymphoma | ||||
| Non-Hodgkins Lymphoma | C50403 | Bengtson | More Info | |
A Phase II Trial of Bortezomib (NSC #681239) + Lenalidomide (Revlimid, CC-5013) (NSC #703813) for Relapsed/Refractory Mantle Cell Lymphoma | ||||
| Non-Hodgkins Lymphoma | C50501 | Bengtson | More Info | |
A Phase III Multicenter, Open-Label Study Of Rituximab Faster Infusion Time in Patients with Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma | ||||
| Non-Hodgkins Lymphoma | F0840 | Bengtson | More Info | |
A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma | ||||
| Non-Hodgkins Lymphoma | F0843 | Bengtson | More Info | |
